Human leukocyte antigen (HLA)-E is a non-classical molecule ofthe histocompatibility complex that functions as one of the main ligands of the Natural Killer (NK) cell inhibitory receptor CD94INKG2A and inhibits its potent cytotoxic activity. Due to the important role of NK cells in combating neoplasm, we hypothesized that the differential expression of HLA-E could favor the progression of heterogeneous thyroid tumors. Using an immunohistochemistry technique in 143 biopsies of thyroid tumors, including benign and malignant neoplasms and goiters, we evaluated the expression of HLA-E among various tumor types and its association with the clinicopathological factors of diseases. We verified high HLA-E expression in all types of neoplastic tumors, although no significant differences between the groups were found. Low expression was observed in 95% of the goiter samples, showing significant differences between neoplastic and non-neoplastic lesions. Furthermore, a significant result was found with regard to the tumor size, with high HLA-E expression being related to smaller tumors. Therefore, our data suggest that an increase in HLA-E may be associated with the establishment of thyroid neoplasms, with either benign or malignant features.
The concept of immunosurveillance has been refined over time, with the emergence of a new term, immunoediting, which describes the ability of selective pressure of the immune system to shape the phenotype of tumor cells. However, this process generates fewer immunogenic cells that, when reaching the clinically detectable stage, do not induce effective responses, resulting in the progression of neoplasia (l). This situation can occur due to structural or functional changes in neoplastic cells, with the alteration ofHLA class I molecules being the mechanism most widely used for escape. Although tumor cells deficient in HLA-I expression may escape from T cells, they remain susceptible to NK cell lysis (2) . NK cells represent the main innate immunity pathway effector response to tumors and were first recognized by their potent ability to kill tumor cells due to their intracellular cytotoxic granules, without prior receptor stimulation (3) . However, to avoid NK attack, tumor cells have developed escape mechanisms based on the aberrant expression of nonclassical HLA molecules or HLA-Ib (4) . Discovered in the 1980s, HLA-Ib molecules are cell surface glycoproteins represented by HLA-E, HLA-F, and HLA-G and are classified as non-classical because they exhibit features that are different from the classical HLAs, including limited polymorphism (5) . The most important function that has been proposed for non-classical HLAs is the regulation of immune cells, mainly NK cells (6) ; in particular, HLA-E has been identified as one of the major mediators of the inhibition of the NK lytic process, functioning as a ligand for the CD94/NKG2A inhibitory receptors of these cells and thereby favoring tumor cells (7) . Some studies have indicated HLA-E expression as a mechanism to escape the immune system in various types of malignancies (8) (9) (10) (11) . Nevertheless, the expression and function of HLA-E in physiological and pathological processes remain poorly understood and need to be better explored (12) . Thyroid neoplasms are the most common endocrine tumors worldwide, and, despite representing only I% of all malignant neoplasms, their incidence rate has been gradually increasing in recent decades in many countries (13) . This increase in incidence is strongly related to technological advances. However, the high frequency of larger tumors (~5 em), which are less likely to be an incidental finding, suggests that improved diagnosis does not completely explain this trend and that other factors, including such environmental factors as the exposure to ionizing radiation, can be additional causes (14) . Papillary carcinoma is the most frequent type of tumor originating from follicular cells and is also the main cause of the increased incidence, being responsible for approximately 80% of cases. The next most common type is follicular carcinoma, with 15% of all cases, followed by anaplastic carcinoma, with less than 2%; medullary carcinoma originating from thyroid parafollicular cells represents approximately 3% (13, 15, 16) . HLA-E has been known to affect the clinical outcome of various tumor types because its interaction with the CD94/NKG2A receptor inhibits the potent anticancer activity of NK cells. Due to the high phenotypic heterogeneity of thyroid tumors (17, 18) , the evaluation of HLA-E in these tumors is an important tool for exploring the process of thyroid neoplasm progression. Based on this evidence, we evaluated the immunohistochemical expression of HLA-E in neoplastic and non-neoplastic lesions to determine the expression pattern among different tumor types and to analyze the impact of HLA-E expression on clinical outcomes.
MATERIALS AND METHODS

Specimens
A total of 122 biopsies of thyroid neoplasms were selected from the archives of the Pathology Department, Faculty of Medicine of Ribeirao Preto (FMRP), University of Sao Paulo, all from the period 1999 to 2012: 73 papillary carcinomas, 18 follicular carcinomas, 8 medullary carcinomas, 3 anaplastic carcinomas, and 20 follicular adenomas. In addition, 21 biopsies of goiters, representing non-neoplastic lesions, and 5 normal thyroids were included. Only blocks oftissues showing no autolysis, artifacts, or signs of inadequate processing were used. The carcinomas were staged by the size ofthe tumor, lymph node metastases, and distant metastases according to the criteria defined by the American Joint Committee on Cancer (AJCC, 2002) and reviewed by the American Thyroid Association (ATA). Clinicopathological information, such as age, sex, recurrence, metastases, and deaths, were collected from reports of the service records of the FMRP Hospital. The study protocol was approved by the Brazilian Institutional Ethics Committee on Human Experimentation (12005/2010), School of Medicine of Ribeirao Preto, University of Sao Paulo.
Immunohistochemistry
Sections of 5 urn were cut, placed on organosilane pretreated slides, and subjected to an immunohistochemistry assay for glycoprotein HLA-E staining using monoclonal MEM-E/02 antibodies (clone MEM-E/02, EXBIO Antibodies, Czech Republic).
The thyroid specimens were dewaxed in xylene, rehydrated in a graded alcohol series, and rinsed in water. For antigen retrieval, the sections were immersed in 10 mM sodium citrate buffer (pH 6.0) and subjected to steam heating for 40 min at 95°C. Blocking of endogenous peroxidase was performed with 3% hydrogen peroxide for 20 min, and nonspecific site binding was performed with horse serum diluted 1:50 in PBS. The primary antibody was used at a 1:100 dilution overnight in a humid chamber, followed by probe incubation for 15 min and polymer (universal HRP-Polymer kit MACH 4™, Concord, CA, USA) incubation for 30 min. The samples were then incubated with 3,3-diaminobenzidine (Gibco; Gaithersburg, MD) diluted in 0.01% HP2 for 10 min and lightly counterstained with Harris hematoxylin for 60 s; after rehydration of the sections in solutions of absolute alcohol and xylene, the slides were mounted with Permount (MERCK; Darmstadt, Germany). 
Immunostaining evaluation
The evaluation ofHLA-E included the staining intensity and the proportion of positive cells within the tumors. The staining intensity was classified as weak (when the cells had slight staining) or strong (when the cells exhibited moderate and severe staining). The estimated fraction of positive cells or semi-quantitative analysis was performed using the following grading system according to the criterion established by the HLA and Cancer component of the 12th International Histocompatibility Workshop (19, 20) : ::0:25% (negative expression), 25%-75% (low expression), 75%-100% (high expression). 
Statistical analyses
Considering that the data did not show a Gaussian distribution, a semi-quantitative statistical analysis to compare the median expression of HLA-E in relation to the histopathological diagnosis was applied using the non-parametric Kruskal-Wallis test, followed by Dunn's multiple comparison post-test. The ''f exact test was used for the semi-quantitative evaluation of HLA-E according to the high or low expression of glycoprotein with the histopathological diagnosis and clinicopathological parameters. The survival rate was assessed using the Kaplan-Meier method, and differences between the curves were analyzed by a log-rank test. All of the analyses were performed with SPSS Statistics Data Editor. A 5% level of significance (a=0.05) was considered for the rejection of the null hypothesis.
RESULTS
HLA-E expression in thyroid tumors
Among the thyroid neoplasm samples evaluated, Fig. 1 
Fig. 2. HLA-E expression determined by immunohistochemistry. A, B) High expression in DTC (differentiated thyroid carcinomas); C) Low expression in TFA (thyroidfollicular adenomas); D) Low expression in goiters; E) Low expression in normal thyroid tissues.
follicular carcinoma. Interestingly, in medullary carcinoma, which originates from the parafollicular cells of the thyroid, the median was 35%, a much lower value when compared to neoplasms arising from follicular cells. In the goiters, the median was also low, equal to 40%, as was the normal gland median, at 20%. Due to the low sample size of medullary, anaplastic, and follicular carcinomas, statistical tests were applied to the groups of differentiated thyroid carcinomas (DTC), thyroid follicular adenomas (TFA), and goiters. In relation to the median expression, the semi-quantitative analysis showed that DTC and TFA had higher values compared to the goiters (p=O.OO I) (Fig. I) ; according to the high or low expression of glycoprotein, the HLA-E evaluation showed a predominance of high expression in DTC and TFA and low expression in goiters (Table I) .
In terms ofthe qualitative analysis, a significantly strong expression in DTC and TFA was observed when compared to the goiter group (Table II) . The normal glands showed only weak staining (Fig. 2) .
HLA -E expression and neoplasm clinicalparameters:
No significant associations were observed regarding HLA-E expression in relation to sex, age, metastasis, stage, recurrence, or death. Significant results were found only in relation to the tumor size in patients with DTC, showing that tumors with a (Table III) .
DISCUSSION
To avoid NK cell attack, tumors have developed escape strategies through the overexpression of nonclassical HLA molecules, such as HLA-E (2, 21) . Several studies have linked the expression ofHLA-E to the clinical and histological characteristics of tumors, and different results have been observed (11, (22) (23) (24) (25) . In the Mittelbronn et al. study, an increase in HLA-E was observed as enhancing the malignancy in diffusely infiltrating astrocytomas (25) .
Similarly, the study of Levy et al. verified that the mean HLA-E expression in more aggressive colorectal carcinomas was higher than in the less aggressive type (11) . In the present study, we show for the first time that a significant fraction of thyroid neoplasms overexpress HLA-E. Immunohistochemistry revealed the enhanced expression of HLA-E in goiters and a massive overexpression in follicular cell neoplasms compared to normal thyroid tissue and parafollicular cell neoplasm (medullary carcinoma). However, despite this high expression, no significant difference was observed when comparing the expression of HLA-E between DTC and TFA. Significant differences were found only among the neoplastic and non-neoplastic lesions.
Considering the high heterogeneity of thyroid tumors, the presence of phenotypic variants suggests that follicular adenoma can become follicular carcinoma (26) . Hence, our results indicate two hypotheses: i) that same adenomatous lesions included in this study demonstrate this processing capacity, conferring the molecular characteristics of malignancy, or ii) that thyrocytes are capable of expressing the molecule in the early neoplastic stage, as occurs in primary melanomas (27) . The second hypothesis is favored when considering that the expression ofHLA-E was significantly higher in the smaller tumors of the DTC group.
Nevertheless, since the first description ofHLA-E on cancer cells, many controversial results have indicated the need for studies of diverse cell types.
By linking the molecule with clinical parameters, it was demonstrated that the high expression of HLA-E was related to a worse prognosis of ovarian carcinoma patients. However, in recent reviews, Benevolo et al. (2011) and Kren et al. (2011) report the opposite in colorectal carcinomas and glioblastomas (23, 28) , with both reporting that the high HLA-E expression is related to a better prognosis. This counterintuitive effect could be explained by the direct engagement of HLA-E with NKG2C activation receptors instead of NKG2A inhibitory receptors (29) . Another explanation could be the binding of HLA-E to peptides not derived from the leader sequence of the classical molecules during the process of glycoprotein stabilization in the endoplasmic reticulum. Such peptides could interfere with the recognition of the HLA molecule by the CD94NKG2A receptor (30) . Interestingly, in relation to survival, Kruijif et al. (2010) showed that breast carcinoma patient survival decreased when HLA-E increased and the samples showed reduced classical HLA molecules. Nevertheless, there were no significant results without the loss of classical HLA (8), similar to our study.
In conclusion, our findings show for the first time that low HLA-E expression is found in nonneoplastic lesions, whereas thyroid neoplasms exhibit a high expression of the molecule, independent of the malignancy and aggressiveness of the type of thyroid tumor.
In fact, HLA-E molecule regulation can differ between different tumor types, reflecting the uniqueness of the cells, pathogenesis, and tumor microenvironment. However, it is clear that an increase in HLA-E is strongly related to the establishment of thyroid neoplasm.
